Upregulation of CLDN6 expression is associated with sorafenib resistance, a standard therapy for advanced HCC, by slowing cell proliferation and increasing both YAP1/TAZ abundance and nuclear translocation (52). The gene discussed is YAP1; the disease is hepatocellular carcinoma.